[{"id":"4d3523b7-5a48-4556-bf2d-8221ac69bbc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720026","created_at":"2023-02-09T15:00:08.134Z","updated_at":"2025-02-25T13:54:54.955Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer","source_id_and_acronym":"NCT05720026","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • SYSA1901 (pertuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 02/21/2026","study_completion_date":" 02/21/2026","last_update_posted":"2023-02-09"}]